Episodes

  • Stocks to Watch: What's Next for the Mighty Dollar?
    Nov 14 2022
    Barron's senior managing editor Lauren R. Rublin, deputy editor Ben Levisohn and Aaron Hurd, managing director of State Street Global Advisors, discuss the outlook for the U.S. dollar, the crypto implosion, and retailers' earnings.
    Show more Show less
    37 mins
  • Managing Your Money: The Case for Investing in Small-Cap Stocks
    Nov 11 2022
    Join Barron's senior writer Lauren Foster and longtime investor Nicholas F. Galluccio, portfolio manager at Teton Advisors, a $1.6 billion asset manager that specializes in micro cap and small cap stocks, for a conversation about the outlook for small caps and the sectors and companies that look attractive going into 2023.
    Show more Show less
    31 mins
  • What to Watch on Election Day as Americans Decide Control of Congress
    Nov 8 2022
    Americans are casting their ballots in the midterm elections, with control of Congress at stake. Join as the MarketWatch Washington bureau leads a discussion of what to watch this Election Day, including key states that will determine the balance of power, the issues driving voters to the polls, and what it could all mean for the economy and markets.
    Show more Show less
    36 mins
  • Stocks to Watch: Talking Markets with J.P. Morgan's David Kelly
    Nov 7 2022
    Barron's senior managing editor Lauren R. Rublin, deputy editor Ben Levisohn and David Kelly, Chief Global Strategist of J.P. Morgan Asset Management discuss the outlook for the economy, interest rates, financial markets, and corporate earnings.
    Show more Show less
    31 mins
  • What Lies Ahead for the Art Market
    Nov 4 2022
    Clare McAndrew, founder of Arts Economics, will discuss her mid-year snapshot of the global art market for Art Basel and UBS with Penta senior writer Abby Schultz ahead of a landmark series of New York auctions including the sale of Paul Allen’s US$1 billion collection.
    Show more Show less
    32 mins
  • An Update on Healthcare Investing
    Nov 3 2022
    Barron's senior managing editor Lauren R. Rublin and healthcare industry reporter Josh Nathan-Kazis discuss drug companies' latest earnings, the latest news on Covid-19 treatments and vaccines, and the outlook for healthcare stocks.
    Show more Show less
    33 mins
  • MarketWatch - Why Isn't America Building Enough Homes?
    Nov 2 2022
    MarketWatch real-estate reporter speaks with UBS analyst John Lovallo about high mortgage rates, waning buyer demand, and why we’re still short of homes in America.
    Show more Show less
    33 mins
  • Tech Trader - The Outlook for Technology Stocks
    Nov 2 2022
    Barron's associate editor for technology Eric Savitz and deputy editor Alex Eule discuss the outlook for technology stocks.
    Show more Show less
    39 mins